2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Antibody

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

ADC Antibody Related Products (123):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990027
    Izeltabart
    		98.62%
    Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer.
    Izeltabart
  • HY-P99285
    Denintuzumab
    		≥99.0%
    Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.
    Denintuzumab
  • HY-P991501
    Meplazumab
    		99.25%
    Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer.
    Meplazumab
  • HY-P99788
    Praluzatamab
    		99.14%
    Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.
    Praluzatamab
  • HY-P99374
    Naratuximab
    		99.9%
    Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine.
    Naratuximab
  • HY-P990059
    Puxitatug
    		99.00%
    Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.
    Puxitatug
  • HY-P990627
    Anti-EphA2 Antibody (1C1)
    		99.9%
    Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma.
    Anti-EphA2 Antibody (1C1)
  • HY-P991728
    Zarutatug
    		99.11%
    Zarutatug (TORL-3-600 antibody) is an IgG1κ humanized antibody targeting cadherin 17 (CDH17). It selectively binds to cell-surface CDH17, triggering endocytosis and trafficking to lysosomes. Zarutatug can be used to construct ADCs, such as TORL-3-600.
    Zarutatug
  • HY-P99785
    Opucolimab
    		99.18%
    Opucolimab (HLX20) is an engineered anti-PD-L1 humanised IgG1 antibody. Opucolimab, when conjugated with camptothecin toxoid, yields the PD-L1-targeting ADC, HLX43 (HY-177439). HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research.
    Opucolimab
  • HY-P991537
    Risvutatug
    		99.57%
    HS-20093 Antibody (GSK5764227 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors.
    Risvutatug
  • HY-P99233
    Camidanlumab
    		99.23%
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Camidanlumab
  • HY-P99034
    Moxetumomab
    		99.77%
    Moxetumomab is an anti-CD22 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Moxetumomab
  • HY-P99970
    Lifastuzumab
    		99.08%
    Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001).
    Lifastuzumab
  • HY-P99718
    Lupartumab
    		99.52%
    Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.
    Lupartumab
  • HY-P991564
    Arcotatug
    		98%
    Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs.
    Arcotatug
  • HY-P99453
    Azintuxizumab
    		≥99.0%
    Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.
    Azintuxizumab
  • HY-145626
    Ozuriftamab
    		99.73%
    Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Ozuriftamab
  • HY-P990896
    FZ-A038
    		99.15%
    FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729).
    FZ-A038
  • HY-P99360
    Enapotamab
    		99.9%
    Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921).
    Enapotamab
  • HY-P99967
    Cantuzumab
    		99.76%
    Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493).
    Cantuzumab